Access Tomorrow's Treatments Today: Our Clinical Trials
Be at the forefront of asthma and COPD innovation. At Advanced Asthma Clinic, led by Dr. Frank Hull, we're not just treating respiratory conditions—we're helping to discover the next breakthrough treatments. Our active research program gives patients access to cutting-edge therapies years before they become widely available.
Benefits of Participating in a Research Study:
- Receive study medications at no cost.
- Potential coverage for other routine respiratory medications through grants.
- Many trials involve FDA-approved drugs being studied for new uses (Phase 4), often with no placebo group.
- All research visits at Dr. Hull's office are free.
- Transportation to research visits is reimbursed.
- All research-related testing (labs, pulmonary function tests, chest imaging if needed) is free.
- Contribute to the future of asthma and COPD care.
- Receive close supervision by respiratory specialists.
- Compensation for time and travel is provided in many studies.
Currently Enrolling Research Studies (as of April 2025):
Please note: This is a summary. Inclusion/exclusion criteria are complex. Contact our research team for details.
Asthma Trials
- Phase 2: For high-risk asthma not currently eligible for biologics (on medium-dose ICS/LABA). Investigates lunsekimig subcutaneous injection. Requires Eos ≥ 300, FeNO ≥ 50, ≥1 exacerbation last year. (Excludes recent biologic use).
- Phase 3b: Open-label (no placebo) study assessing CT changes over 1 year after receiving the IL-5 biologic depemokimab (dosed every 6 months). For patients with Eos ≥ 300, ≥2 exacerbations, on medium/high ICS + another controller. (Excludes prior anti-IL-5/biologic use).
- Phase 2: Dose-finding study for a new Anti-TSLP Antibody (dosed every 6 months). For adults with ≥1 exacerbation last year on medium/high ICS + another controller. (Excludes recent biologic use).
COPD Trials
- Phase 3/4: For patients aged 40-80 with COPD & cardiovascular risk/disease, comparing BREZTRI vs. BEVESPI. Primary goal: Reduce cardiac events (MI/CVA). Requires Eos ≥ 100. Key Exclusion: Cannot have used ICS for more than 2 months in the past year.
- Phase 2b/3: For moderate to very severe COPD with high exacerbation risk (≥2 moderate or ≥1 severe in past year) on triple therapy. Investigates Lunsekimig (novel NANOBODY) targeting IL-13 and TSLP. Requires Eos ≥ 150.
- Phase 4: Open-label (no placebo - all participants get Dupixent). For COPD patients qualifying for Dupixent (Eos ≥ 300, ≥2 exacerbations). Assesses CT changes (mucus plugging).
- Phase 1b: Safety study (no placebo) for a GSK IL-33 antibody. For COPD patients aged 40-75 with Eos ≥ 150. Pays ~$150/visit.
- Phase 3: For COPD exacerbators with TH2 inflammation or eosinophilia. Investigates the IL-5 biologic depemokimab.
Chronic Cough Trial
- Phase 3: For Refractory or Unexplained Chronic Cough (RCC/UCC) lasting ≥ 1 year, unresponsive to standard treatments. Investigates the P2X3 inhibitor camlipixant. Cough Severity VAS ≥ 40 required. Excludes current smokers or recent quitters (<6 months), significant respiratory diseases (COPD, IPF, Bronchiectasis), uncontrolled asthma.
Other studies for COPD and Bronchiectasis may also be available or starting soon.
Is a Clinical Trial Right for You?
Clinical trials may be particularly beneficial if:
- Your asthma or COPD is not well-controlled with current treatments available in the Plantation, FL area.
- You experience frequent exacerbations (flare-ups requiring steroids or hospitalization).
- You are looking to reduce your dependence on oral steroids (like prednisone).
- Standard treatments haven't provided sufficient relief or have caused side effects.
- You have specific types of inflammation (e.g., high eosinophils) or conditions like chronic cough that match our study criteria.
- You want access to potentially groundbreaking therapies at no cost while under the care of Dr. Hull.
Our research coordinators will carefully review your medical history to help determine if you might qualify for one of our studies.